.jpg?format=webp&width=780)
In AFFIRM‐AHF, intravenous ferric carboxymaltose (FCM) reduced heart failure (HF) hospitalisations and improved quality of life versus placebo in iron‐deficient patients stabilised after an acute HF episode. This analysis explored the effects of FCM versus placebo in patients with ischaemic and non‐ischaemic HF aetiology. Heart failure hospitalisations and cardiovascular deaths occurred at a higher rate in patients with ischaemic versus those with non‐ischaemic HF. However, FCM versus placebo reduced them only in ischaemic patients. Further studies are needed to assess the role of aetiology in FCM efficacy.
Like
Save
Share